Financials data is unavailable for this security.
View more
Year on year Zhejiang CONBA Pharmaceutical Co Ltd grew revenues 12.20% from 6.00bn to 6.73bn while net income improved 65.20% from 358.10m to 591.57m.
Gross margin | 52.88% |
---|---|
Net profit margin | 7.90% |
Operating margin | 9.65% |
Return on assets | 4.66% |
---|---|
Return on equity | 6.69% |
Return on investment | 6.76% |
More ▼
Cash flow in CNYView more
In 2023, Zhejiang CONBA Pharmaceutical Co Ltd did not generate a significant amount of cash. However, the company earned 898.64m from its operations for a Cash Flow Margin of 13.35%. In addition the company used 289.05m on investing activities and also paid 719.08m in financing cash flows.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 2.66 |
---|---|
Tangible book value per share | 2.44 |
More ▼
Balance sheet in CNYView more
Current ratio | 1.77 |
---|---|
Quick ratio | 1.30 |
Total debt/total equity | 0.1276 |
---|---|
Total debt/total capital | 0.109 |
More ▼